US Pharm. 2009;34(9):34-36.As part of its strategy to expand its business horizons, Greenstone LLC, the generic pharmaceutical subsidiary of Pfizer Inc., announced two key management appointments.
To help the company identify and expand developing initiatives that are evolving in the U.S. generic market, Greenstone LLC appointed a 25-year veteran of the generic industry, Christine Versichele, to the position of director of U.S. generic channel strategies.
With the rapid growth of the Greenstone product line, Ms. Versichele's role has been expanded to include responsibilities for identifying and developing initiatives to help drive the company's alignment with the evolving U.S. generic market. Ms. Versichele has previously managed sales and marketing programs with retail, institutional, and governmental health care providers. In her new role, she will be responsible for positioning Greenstone to achieve its business objectives by working with key strategic channel partners in creating and implementing innovative and competitive sales and policy solutions.The company also announced the appointment of Mark Mancinotti to the position of national account director. For more than 25 years, Mr. Mancinotti focused primarily on national and regional accounts. Over that time he directed sales and marketing programs to retail, institutional, governmental, and managed care organizations, as well as health care providers. In his new role he will be responsible for positioning Greenstone to achieve its business objectives by working with key national and regional account partners to create and implement innovative and competitive sales solutions for the expanding Greenstone product line.